Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.
作者信息
Alayo Quazim A, Khatiwada Aava, Patel Anish, Zulfiqar Maria, Gremida Anas, Gutierrez Alexandra, Rood Richard P, Ciorba Matthew A, Christophi George, Deepak Parakkal
机构信息
Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA.
Department of Internal Medicine, St. Luke's Hospital, Chesterfield, Missouri, USA.
出版信息
Inflamm Bowel Dis. 2021 Oct 18;27(10):1698-1702. doi: 10.1093/ibd/izab112.
Abstract
摘要
相似文献
1
Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.
Inflamm Bowel Dis. 2021 Oct 18;27(10):1698-1702. doi: 10.1093/ibd/izab112.
2
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
Drugs. 2020 Jul;80(11):1085-1100. doi: 10.1007/s40265-020-01346-4.
3
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2020 Jan;18(1):69-81.e3. doi: 10.1016/j.cgh.2019.02.044. Epub 2019 Mar 12.
4
Safety comparison of therapies used in inflammatory bowel disease.
J Gastroenterol Hepatol. 2021 Apr;36 Suppl 1:20-21. doi: 10.1111/jgh.15453.
5
Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease.
Aliment Pharmacol Ther. 2019 Oct;50(8):966-967. doi: 10.1111/apt.15496.
6
Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2021 Jul 27;27(8):1210-1214. doi: 10.1093/ibd/izaa277.
7
Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.
Inflamm Bowel Dis. 2019 May 4;25(6):955-957. doi: 10.1093/ibd/izy387.
8
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
Rheumatology (Oxford). 2014 Oct;53(10):1872-85. doi: 10.1093/rheumatology/keu172. Epub 2014 May 11.
9
Q: Is it safe to continue biologic agents during surgery in patients with inflammatory bowel disease?
Cleve Clin J Med. 2020 Jun;87(6):343-346. doi: 10.3949/ccjm.87a.19071.
10
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2207-2209.e3. doi: 10.1016/j.cgh.2020.10.025. Epub 2020 Oct 14.
引用本文的文献
1
Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan.
J Inflamm Res. 2025 Feb 26;18:2733-2742. doi: 10.2147/JIR.S511309. eCollection 2025.
2
Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective Study.
Crohns Colitis 360. 2024 Oct 23;7(1):otae057. doi: 10.1093/crocol/otae057. eCollection 2025 Jan.
3
Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China.
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241307598. doi: 10.1177/17562848241307598. eCollection 2025.
4
Recent Advances in the Management of Acute Severe Ulcerative Colitis.
J Clin Med. 2024 Dec 6;13(23):7446. doi: 10.3390/jcm13237446.
5
Advanced combination therapy: is it the best way to break the therapeutic ceiling?
Therap Adv Gastroenterol. 2024 Oct 24;17:17562848241272995. doi: 10.1177/17562848241272995. eCollection 2024.
6
Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.
Clin Exp Gastroenterol. 2024 Oct 10;17:261-315. doi: 10.2147/CEG.S434014. eCollection 2024.
7
Precision medicine in inflammatory bowel disease.
Precis Clin Med. 2023 Dec 18;6(4):pbad033. doi: 10.1093/pcmedi/pbad033. eCollection 2023 Dec.
8
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.
J Can Assoc Gastroenterol. 2023 Sep 26;7(1):22-29. doi: 10.1093/jcag/gwad032. eCollection 2024 Feb.
9
Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease.
World J Gastroenterol. 2022 Dec 21;28(47):6743-6751. doi: 10.3748/wjg.v28.i47.6743.
10
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Drugs Context. 2022 Apr 8;11. doi: 10.7573/dic.2021-11-4. eCollection 2022.
本文引用的文献
1
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1592-1601.e3. doi: 10.1016/j.cgh.2020.06.050. Epub 2020 Jul 3.
2
Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib.
Inflamm Bowel Dis. 2020 Oct 23;26(11):e146. doi: 10.1093/ibd/izaa158.
3
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719. Epub 2020 Apr 24.
4
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study.
J Dig Dis. 2020 May;21(5):264-271. doi: 10.1111/1751-2980.12867. Epub 2020 Jun 11.
5
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.
6
Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease.
Gastroenterology. 2019 Aug;157(2):432-439.e1. doi: 10.1053/j.gastro.2019.03.051. Epub 2019 Apr 3.
7
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
Clin Gastroenterol Hepatol. 2019 Mar;17(4):794-796. doi: 10.1016/j.cgh.2018.08.017. Epub 2018 Aug 13.
8
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
Aliment Pharmacol Ther. 2017 Mar;45(6):801-813. doi: 10.1111/apt.13948. Epub 2017 Jan 23.
9
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
Inflamm Bowel Dis. 2015 Dec;21(12):2879-85. doi: 10.1097/MIB.0000000000000561.
Zotero 插件